All News
Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - from newsworthy to routine. Now that much more about CAR-T has been worked out, will adoption be quicker in autoimmune disease? #ACR25 BCRC pre-meeting @RheumNow https://t.co/oNuPXCwWQ9
Links:
David Liew drdavidliew ( View Tweet)
What to use in future for active #Sjogren's #SjD
B cell depletion, signal attenuation
Ianalumab 2+ phase3 RCTs
Telitacept +RCT
Nipocalimab FcRn +Ph2
Dazodalibep CD40L +Ph2
+RCTs
HCQ+Lef
Rituximab
?BTKi
#ACR25 @ACRheum @RheumNow
abst#LB24, LB11
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Next Generation T-Cell Engager: The Future
Dr. Alfred Kim reviews abstract 0001 presented at #ACR25.
https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
CAR-T Cell Therapies Show Promise for Autoimmune Disease
Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Dr. John Cush RheumNow ( View Tweet)
Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis?
Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate
Improvemt in #clinical #disease #activity
less inflammation on #synovial #biopsies 3 pts
#LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx
Janet Pope Janetbirdope ( View Tweet)
#PD1 Ab looks good and safe in active RA
Rosnilimab, a Selective and Potent Depleter of Pathogenic T
Many failed several Rx already
No safety signals compared to another PD1i
Proof of benefit in biospecimens too!
abst#LB19 #ACR25 @RheumNow @ACRheum
#ACRBest https://t.co/TmEOCfuHZU
Links:
Janet Pope Janetbirdope ( View Tweet)
TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation):
🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol
🔹similar adverse events reported (14.6% vs 16.4%)
@RheumNow #ACR25 https://t.co/Yuql3O9C8X
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Older Adults Underrepresented in RCTs
Drs. Jiha Lee and Sebastian Sattui discuss abstract 1072, "Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review," presented at #ACR25
https://t.co/uzSPH5RbjM https://t.co/94Vw6qUOIL
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstract 2697: Compared to MMF, tacrolimus showed
- similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29)
- similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35)
- serious AEs less frequent (12.3% vs. 30.8%)
@RheumNow #ACR25 https://t.co/o3LtgOp7St
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#2658 In >870k adults with T2DM or obesity, GLP-1 receptor agonists showed no increase in autoimmune or inflammatory disease risk, and were instead linked to lower mortality, heart failure, stroke and dementia. Excellent real-world safety signals. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Abstract 2695: Deep dive into B-cell depletion (BCD)
Lymph node biopsy pre/post tx:
🔹 CAR T: complete BCD + disrupted follicular architecture
🔹 RTX, OBI, BLIN: reduced BCD + preserved follicular architecture
✅ Complete LN depletion → drug-free remission
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
This prospective study from Brazil evaluated the effect of RHZ vax in SSc pts
SSc pts had ⬆️rates of seroconversion
mean titers ⬆️ from BL
Local rxs ⬇️ in SSc pts
Systemic rxns comparable among the 2 grps
interesting data. longterm studies still needed
#ACR25 @RheumNow Abs2653 https://t.co/wJqpPrAHKG
Links:
sheila RHEUMarampa ( View Tweet)
Trends in Translational Abstracts content this year by Tomas Mustelin in the
“Abstracts that Will shape research in the near Future” Year in Preview session
@RheumNow #ACR25 https://t.co/i5CA8cxHeQ
Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Autologous CAR-Treg in RA, without any lymphodepletion preRx
Early data from ph1, single dose
Good initial response, stopped RA Rx, but some rebound
Clearly work ongoing but excitement re:
- CAR-Treg
- RA as target dx
- no lymphodepletion
@minnakohlermd #ACR25 LB23 @RheumNow https://t.co/azmlFNU02R
Links:
David Liew drdavidliew ( View Tweet)
REGULATE RA SBT-77-701
Engineered Treg cell in Refractory RA population
6patients
Safety and tolerability: No DLT, CRS or ICANS
Efficacy
Reduction >50% in TJC and SJC
67% reduction of DAS-CRP >=2
stained up to wk 24
Impressive in pts for whom it works, yet a couple seem to https://t.co/lQAQABPhg0
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#LB23 Phase 1 trial in 5 refractory #RA of SBT777101, a novel autologous CAR-Treg (without the need for lymphodepletion) showed promising efficacy and safety signal. No DLT, CRS or ICANS. Looking forward to larger data and in other RMDs @RheumNow https://t.co/YyGMSHjA3z
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
